By Doug Macron
Alnylam Pharmaceuticals this week unveiled an initiative to apply its RNAi technology to the production of vaccines and announced that GlaxoSmithKline will be its first partner for the platform.
The US Centers for Disease Control said late last week that its newest in vitro diagnostic testing panel for seasonal and pandemic influenza strains has been authorized for use by the US Food and Drug Administration.
By a GenomeWeb staff reporter
NEW YORK (GenomeWeb News) – The US Food and Drug Administration has given 510(k) clearance to IQuum's assay for detecting and differentiating influenza A and B in about 20 minutes, the company announced today.